|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Comparison of the transcriptome data of metastasis-competent CTC-MCC-41 cells and of HT-29 cells (derived from a primary colon cancer) highlights the differential expression of genes that regulate energy metabolism [peroxisome proliferator-activated receptor γ coactivator 1A (<i>PPARGC1A</i>), peroxisome proliferator-activated receptor γ coactivator 1B (<i>PPARGC1B</i>), fatty acid binding protein 1 (<i>FABP1</i>), aldehyde dehydrogenase 3 family member A1 (<i>ALDH3A1</i>)], DNA repair [BRCA1 interacting protein C-terminal helicase 1 (<i>BRIP1</i>), Fanconi anemia complementation group B (<i>FANCB</i>), Fanconi anemia complementation group M (<i>FANCM</i>)], and stemness [glutaminase 2 (<i>GLS2</i>), cystathionine-beta-synthase (<i>CBS</i>), and cystathionine gamma-lyase (<i>CTH</i>)].
|
28007957 |
2017 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1.
|
16155208 |
2005 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We also correlated EZR and PPARγ expression in our series of CRC specimens and the expression profiling of all five proteins levels in the publicly available colon cancer genomic data from Oncomine and Cancer Genome Atlas (TCGA) colon adenocarcinoma (COAD) datasets.
|
27499265 |
2016 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer.
|
28298922 |
2017 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Stratified meta-analysis indicated that PPAR-gamma 34 C>G was associated with colon cancer (OR = 0.8, 95% CI: 0.65-0.99, P = 0.04) in random-effect model, and the G allele decreased colon cancer risk.
|
20440859 |
2010 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that PPARgamma plays a role as a physiological regulator of colonic epithelial cell turnover and consequently predisposition to the development of colon cancer in early stage.
|
18391483 |
2008 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
High lutein intake [odds ratio (OR), 0.63; 95% confidence interval (95% CI), 0.44-0.89], low refined grain intake (OR, 0.70; 95% CI, 0.53-0.94), or a high prudent diet score (OR, 0.66; 95% CI, 0.49-0.89) and PA/AA PPARgamma genotype were associated with reduced colon cancer risk.
|
15894676 |
2005 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We observed a marked synergism between peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and X-linked inhibitor of apoptosis (XIAP) down-regulation in colon cancer.
|
18704457 |
2009 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression of this protein may prevent PPARgamma ligand efficiency in colon cancer treatment.
|
17611675 |
2007 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists.
|
30931956 |
2019 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, FPLD3-associated PPARγ mutations consistently cause intra- and/or intermolecular defects; colon cancer-associated PPARγ mutations on the other hand may play a role in colon cancer onset and progression, but this is not due to their effects on the most well-studied functional characteristics of PPARγ.
|
30595551 |
2019 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'indolyl)-1-(p-substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF)), p-t-butyl (DIM-C-pPhtBu), and p-phenyl (DIM-C-pPhC6H5) groups induce peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated transactivation in HT-29, HCT-15, RKO, and SW480 colon cancer cell lines.
|
15342379 |
2004 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.
|
12946234 |
2003 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR-gamma), a member of the nuclear hormone receptor superfamily, is involved in suppression of growth of several types of tumors such as liposarcoma, breast cancer, prostate cancer, and colon cancer, possibly through induction of cell cycle arrest and/or apoptosis.
|
11494023 |
2001 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, PPARgamma protein levels are elevated, possibly through sequestration by activated beta-catenin in colon cancer cell lines.
|
15665104 |
2005 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand that has pro-apoptotic activity in human colon cancer.
|
12475986 |
2003 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, SOX9, β-catenin and PPARγ expression levels are deregulated in the CRC tissue, and in colon cancer cell lines ligand-dependent PPARγ activation unevenly influences SOX9 and β-catenin expression and subcellular localization, suggesting a variable mechanistic role in colon carcinogenesis.
|
23583560 |
2013 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated if the rexinoid 6-OH-11-O-hydroxyphenantrene (IIF) potentiates the antitumoral properties of PPARgamma ligands as ciglitazone and pioglitazone, on two colon cancer cell lines: HCA-7 and HCT-116.
|
20510503 |
2010 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The activation of peroxisome proliferator-activated receptor gamma stimulated by thiazolidinedione is useful in the treatment of type II diabetes mellitus and may have value in preventing inflammatory bowel disease or colon cancer.
|
12946210 |
2003 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
To investigate the relationship between PSF and PPARγ in colon cancer, we evaluated the effects of PSF expression in DLD-1 and HT-29 colon cancer cell lines, which express low and high levels of PPARγ, respectively PSF affected the ability of PPARγ to bind, and expression of PSF siRNA significantly suppressed the proliferation of colon cancer cells.
|
23516550 |
2013 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
We can therefore exclude this alteration as a mechanism of resistance to PPAR(gamma) ligands in patients with colon cancer.
|
15911106 |
2005 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This suggests that PPARγ expression may be an important factor for cell growth regulation in colon cancer.
|
22771328 |
2012 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Therefore, dihydroartemisinin inhibits colon cancer growth by inducing apoptosis and increasing the expression of PPARγ.
|
29472793 |
2018 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines.
|
19551868 |
2009 |